CA2427617A1 - Medicinal compositions for concomitant use as anticancer agent - Google Patents
Medicinal compositions for concomitant use as anticancer agent Download PDFInfo
- Publication number
- CA2427617A1 CA2427617A1 CA002427617A CA2427617A CA2427617A1 CA 2427617 A1 CA2427617 A1 CA 2427617A1 CA 002427617 A CA002427617 A CA 002427617A CA 2427617 A CA2427617 A CA 2427617A CA 2427617 A1 CA2427617 A1 CA 2427617A1
- Authority
- CA
- Canada
- Prior art keywords
- ring
- salt
- substituent group
- anticancer agent
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula:
(see formula above) (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group;
W represents a single bond or -CH=CH-; X represents -NH- etc. ;
and Y represents a carbon atom or a nitrogen atom; and Z
represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil;
(4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin;
(7) taxol; and (8) a salt of the above-mentioned (1) to (7).
(see formula above) (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group;
W represents a single bond or -CH=CH-; X represents -NH- etc. ;
and Y represents a carbon atom or a nitrogen atom; and Z
represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil;
(4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin;
(7) taxol; and (8) a salt of the above-mentioned (1) to (7).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000333952 | 2000-10-31 | ||
JP2000-333952 | 2000-10-31 | ||
PCT/JP2001/009563 WO2002036117A1 (en) | 2000-10-31 | 2001-10-31 | Medicinal compositions for concominant use as anticancer atent |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2427617A1 true CA2427617A1 (en) | 2003-04-29 |
CA2427617C CA2427617C (en) | 2009-10-06 |
Family
ID=18809950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002427617A Expired - Fee Related CA2427617C (en) | 2000-10-31 | 2001-10-31 | Medicinal compositions for concomitant use as anticancer agent |
Country Status (12)
Country | Link |
---|---|
US (3) | US20040002505A1 (en) |
EP (1) | EP1331005B1 (en) |
JP (1) | JP4167898B2 (en) |
KR (1) | KR100829875B1 (en) |
CN (1) | CN1196484C (en) |
AT (1) | ATE322264T1 (en) |
AU (2) | AU1099302A (en) |
CA (1) | CA2427617C (en) |
DE (1) | DE60118590T2 (en) |
NZ (1) | NZ524975A (en) |
TW (1) | TWI283575B (en) |
WO (1) | WO2002036117A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60134679D1 (en) | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Nitrogen-containing aromatic heterocycles |
US7994159B2 (en) * | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
DE602004010900D1 (en) * | 2003-05-08 | 2008-02-07 | Eisai R&D Man Co Ltd | MEDICAL COMPOSITIONS CONTAIN N- (3-CHLORO-1H-INDOL-7-YL) -4-SULFAMOYL-BENZENESULFONAMIDE AND OTHER CYTOSTATICS |
US20070037854A1 (en) * | 2003-09-10 | 2007-02-15 | Kenji Hayashi | Process for preparing sulfonamide-containing indole compounds |
WO2005026118A1 (en) * | 2003-09-10 | 2005-03-24 | Eisai Co., Ltd. | Crystal of sulfonamide-containing indole compound and process for producing the same |
JP4303726B2 (en) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Urea derivative and method for producing the same |
CZ2006427A3 (en) * | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
WO2005082397A1 (en) * | 2004-02-26 | 2005-09-09 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
US20090047365A1 (en) * | 2005-02-28 | 2009-02-19 | Eisai R & D Management Co., Ltd. | Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent |
CN1313104C (en) * | 2005-05-27 | 2007-05-02 | 中国科学院南海海洋研究所 | Anticancer medicine composition with synergistic bupleurum root and polymyxin |
MX2008000250A (en) | 2005-07-06 | 2008-03-19 | Sepracor Inc | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2, 3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive dis |
JP5066446B2 (en) * | 2005-08-01 | 2012-11-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods for predicting the effects of angiogenesis inhibitors |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Method for assay on the effect of vascularization inhibitor |
CA2620594C (en) * | 2005-09-01 | 2012-08-21 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition having improved disintegratability |
CN101316590B (en) * | 2005-11-07 | 2011-08-03 | 卫材R&D管理有限公司 | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Anti-tumor agent for multiple myeloma |
ES2566479T3 (en) * | 2006-01-06 | 2016-04-13 | Sunovion Pharmaceuticals Inc. | Monoamine reabsorption inhibitors based on tetralone |
AU2007205114B2 (en) | 2006-01-06 | 2012-11-08 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
CN101421228B (en) | 2006-03-31 | 2014-05-21 | 塞普拉柯公司 | Preparation of chiral amides and amines |
ES2556173T3 (en) * | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
US20080058395A1 (en) * | 2006-06-30 | 2008-03-06 | Sepracor Inc. | Fused heterocyclic inhibitors of D-amino acid oxidase |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
MX2009007410A (en) * | 2007-01-18 | 2009-09-09 | Sepracor Inc | Inhibitors of d-amino acid oxidase. |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
US8669291B2 (en) | 2007-05-31 | 2014-03-11 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
CN101848895B (en) * | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | Combination of anti-angiogenic substance and anti-tumor platinum complex |
AU2009210098B2 (en) * | 2008-01-29 | 2013-06-13 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
CN101584696A (en) * | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | Composition containing quinazoline derivatives, preparation method and use |
WO2010017418A1 (en) * | 2008-08-07 | 2010-02-11 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
US9012458B2 (en) | 2010-06-25 | 2015-04-21 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012144463A1 (en) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Therapeutic agent for tumor |
WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
KR20150098605A (en) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Amorphous form of quinoline derivative, and method for producing same |
KR102204279B1 (en) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
ES2680444T3 (en) * | 2014-01-17 | 2018-09-07 | Oncoral Pharma Aps | Solid oral dosage form of irinotecan for cancer treatment |
RS63559B1 (en) | 2014-08-28 | 2022-10-31 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same |
WO2016094402A1 (en) * | 2014-12-09 | 2016-06-16 | Merrimack Pharmaceuticals, Inc. | Treatment of breast cancer with liposomal irinotecan |
PL3263106T3 (en) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
BR112017027227B1 (en) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | ANTI-CANCER AGENT |
WO2017031445A1 (en) | 2015-08-20 | 2017-02-23 | Merrimack Pharmaceuticals, Inc. | Combination therapy for cancer treatment |
CN108495629A (en) | 2015-08-21 | 2018-09-04 | 益普生生物制药有限公司 | Use the method comprising liposome Irinotecan and the combination therapy to treat metastatic cancer of pancreas of oxaliplatin |
JP2019533684A (en) | 2016-11-02 | 2019-11-21 | イプセン バイオファーム リミティド | Treatment of gastric cancer with combination therapy including liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3545461B2 (en) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | Bicyclic heterocycle-containing sulfonamide derivatives |
ATE255106T1 (en) * | 1993-09-10 | 2003-12-15 | Eisai Co Ltd | BICYCLIC, HETEROCYCLIC SULFONAMIDES AND SULFONIC ACID ESTERS |
JPH09208571A (en) * | 1996-02-02 | 1997-08-12 | Takeda Chem Ind Ltd | Alkylidenecyclohexane derivative |
JP2000143635A (en) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | Arterialization inhibitor |
JP2000247949A (en) * | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | Indole compound containing sulfonamide |
US6911306B1 (en) * | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
EP1296714B1 (en) * | 2000-06-22 | 2009-08-26 | University Of Iowa Research Foundation | Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer. |
-
2001
- 2001-10-30 TW TW090126893A patent/TWI283575B/en active
- 2001-10-31 US US10/381,909 patent/US20040002505A1/en not_active Abandoned
- 2001-10-31 AU AU1099302A patent/AU1099302A/en active Pending
- 2001-10-31 JP JP2002538929A patent/JP4167898B2/en not_active Expired - Fee Related
- 2001-10-31 CN CNB018183581A patent/CN1196484C/en not_active Expired - Fee Related
- 2001-10-31 AT AT01978983T patent/ATE322264T1/en not_active IP Right Cessation
- 2001-10-31 KR KR1020037004463A patent/KR100829875B1/en not_active IP Right Cessation
- 2001-10-31 CA CA002427617A patent/CA2427617C/en not_active Expired - Fee Related
- 2001-10-31 AU AU2002210993A patent/AU2002210993B2/en not_active Ceased
- 2001-10-31 WO PCT/JP2001/009563 patent/WO2002036117A1/en active IP Right Grant
- 2001-10-31 DE DE60118590T patent/DE60118590T2/en not_active Expired - Lifetime
- 2001-10-31 EP EP01978983A patent/EP1331005B1/en not_active Expired - Lifetime
- 2001-10-31 NZ NZ524975A patent/NZ524975A/en unknown
-
2003
- 2003-05-08 US US10/431,569 patent/US20030215523A1/en not_active Abandoned
-
2004
- 2004-05-06 US US10/839,222 patent/US20040224972A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2002210993B2 (en) | 2006-12-07 |
ATE322264T1 (en) | 2006-04-15 |
NZ524975A (en) | 2004-11-26 |
TWI283575B (en) | 2007-07-11 |
AU1099302A (en) | 2002-05-15 |
WO2002036117A1 (en) | 2002-05-10 |
CN1196484C (en) | 2005-04-13 |
CA2427617C (en) | 2009-10-06 |
JP4167898B2 (en) | 2008-10-22 |
CN1473041A (en) | 2004-02-04 |
US20040002505A1 (en) | 2004-01-01 |
US20040224972A1 (en) | 2004-11-11 |
EP1331005B1 (en) | 2006-04-05 |
EP1331005A4 (en) | 2004-12-22 |
EP1331005A1 (en) | 2003-07-30 |
DE60118590D1 (en) | 2006-05-18 |
KR20030046475A (en) | 2003-06-12 |
KR100829875B1 (en) | 2008-05-16 |
JPWO2002036117A1 (en) | 2004-03-11 |
US20030215523A1 (en) | 2003-11-20 |
DE60118590T2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2427617A1 (en) | Medicinal compositions for concomitant use as anticancer agent | |
CA2415010A1 (en) | Propane-1,3-dione derivatives useful as gnrh receptor antagonist | |
IL154350A (en) | Phenylalanine derivatives and pharmaceutical compositions containing them | |
CA2560510A1 (en) | N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides | |
EA200300412A1 (en) | PHARMACEUTICAL ACTIVE DERIVATIVES OF SULPHONAMIDE, CONTAINING AS LYPOPHIL, SO AND IONIZABLE FRAGMENTS, AS AN INHIBITORS JUN-PROTEINKINAZ | |
KR900002784A (en) | Pharmaceutical binding agents for use in antitumor therapy | |
CA2506441A1 (en) | 5-substituted-pyrazine or pyridine glucokinase activators | |
EP1008588A4 (en) | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient | |
CO5580767A2 (en) | INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE | |
MXPA02011974A (en) | Substituted quinazoline derivatives and their use as inhibitors. | |
GB0206860D0 (en) | Compounds | |
IL174665A0 (en) | Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same | |
CA2159450A1 (en) | 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors | |
CA2337825A1 (en) | Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions | |
TW200612920A (en) | Novel imidazolidine derivatives | |
WO2002048148A3 (en) | Pyrazolopyridine derivatives | |
HK1099200A1 (en) | Anti-inflammatory agents | |
NO984470L (en) | Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase | |
WO2003049690A3 (en) | Hiv integrase inhibitors | |
EP1568382A4 (en) | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND beta-BLOCKER | |
WO2003053971A8 (en) | Pyridoquinoxaline antivirals | |
WO2003049676A3 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer | |
CA2140927A1 (en) | Platelet aggregation inhibitors | |
WO2007058568A3 (en) | Salts of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols | |
CA2535210A1 (en) | Novel farnesyl protein transferase inhibitors as antitumor agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |